TEE
KALV

Tibra Equities Europe’s KalVista Pharmaceuticals KALV Stock Holding History

Tibra Equities Europe’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,300
Closed -$250K – 30
2021
Q3 		$250K Buy
+14,300
New +$290K 0.38% 29
2019
Q2 		– Sell
-25,401
Closed -$727K – 357
2019
Q1 		$727K Buy
+25,401
New +$551K 0.07% 213

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tibra Equities Europe's KALV Position: Q4 2021 in Review

Tibra Equities Europe sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 14,300 shares — an estimated $250K sold.

Tibra Equities Europe first reported a position in KALV in Q1 2019 and held it in 2 quarters. The position peaked at $727K in Q1 2019. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

  • Tibra Equities Europe reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 14,300 KalVista Pharmaceuticals shares in Q4 2021, an estimated $250K.
  • Tibra Equities Europe first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Tibra Equities Europe's KalVista Pharmaceuticals position peaked at $727K in Q1 2019.
  • 97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Tibra Equities Europe's 13F filing for Q4 2021, filed 14 Feb 2022.